The 2024 International Expert Consensus on US-guided Thermal Ablation for T1N0M0 Papillary Thyroid Cancer, recently published in RADIOLOGY, establishes new global standards for minimally invasive thyroid cancer treatment.

This landmark consensus shatters previous limitations by expanding thermal ablation eligibility to include T1b tumors (<2cm) and pioneering treatment approval for multifocal PTC, capsular microinvasive PTC, and isthmus PTC. Crucially, it elevates thermal ablation to a first-line therapy – now formally recognized as equally effective as surgery for eligible patient. 

By providing clear clinical guidelines and robust evidence, this consensus will enable more patients worldwide to benefit from organ-preserving treatment options that maintain thyroid function and quality of life. Its publication marks a major advancement in making minimally invasive therapies more accessible and standardized across global clinical practice.

Canyon remains committed to advancing innovative technologies in thyroid ablation to empower better treatment outcomes and improved quality of life for patients worldwide.